Denosumab (Prolia): Why Stopping It Is Different From Every Other Bone Drug

What is denosumab, and why is it prescribed?

Denosumab, sold as Prolia for osteoporosis, is an injection given under the skin every six months. It is a monoclonal antibody that blocks RANK ligand, the signalling protein the body uses to tell bone-resorbing cells to get to work. Block that signal and bone breakdown slows sharply.

It builds bone density steadily and, unlike oral bisphosphonates, does not depend on you taking a tablet correctly on an empty stomach and staying upright afterwards. For many women it is both the more effective and the more tolerable option. It is also usable at lower kidney function than bisphosphonates, which matters more often than people expect. Our page on osteoporosis medications compared puts it alongside the alternatives.

Why is stopping it different from every other bone drug?

This is the part that is frequently not explained, and it is the reason this page exists.

Bisphosphonates bind to the mineral surface of bone and stay there. When you stop, the drug already deposited in the skeleton keeps working for months or years, fading gradually. Denosumab does not bind to bone mineral at all. It circulates, and when it clears, the suppressed bone-resorbing cells return, not to baseline but overshooting it.

This is the rebound phenomenon. Bone turnover markers rise sharply, the density gained during treatment is lost quickly, and spontaneous vertebral fractures have been reported, frequently several at once, in women who had never fractured before. The loss typically happens within 6 to 12 months of a missed or stopped dose. Published estimates of how many women sustain multiple vertebral fractures after stopping without follow-on treatment vary between studies, roughly in the region of 10% and higher in some series.

Two consequences follow, and they are the most practical things on this page:

• A late injection is not a scheduling inconvenience. The six-month interval is not a suggestion. If travel, an insurance change or a move between prescribers is coming, arrange the next dose before the gap rather than after it.
• Stopping is a planned medical transition, not simply not renewing. Denosumab is the one osteoporosis drug you should never quietly discontinue.

How is coming off it actually managed?

The standard approach is antiresorptive bridging: moving to a bisphosphonate to hold the gains. The European Calcified Tissue Society published guidance on this in 2021, and it is the framework most clinicians work from.

Three honest caveats from the literature, none of which usually make it into a consultation:

• Bisphosphonate bridging attenuates but does not fully prevent the bone loss. It reduces the problem rather than eliminating it.
• Raloxifene does not work for this. It was studied specifically as a post-denosumab strategy and failed to control either the high bone turnover or the spontaneous vertebral fracture risk. See our page on raloxifene for where it does fit.
• Individual cases of vertebral fracture despite oral risedronate bridging have been published, so bridging is not a guarantee.

Timing matters as well. In higher-risk patients, switching too early, while density is still low, has been described as increasing rather than reducing rebound fracture risk. This is a decision for a clinician who treats osteoporosis regularly rather than something to read off a webpage. Our guide to stopping osteoporosis medication covers how the classes differ.

How does it compare with a bisphosphonate?

If kidney function is part of your decision, our page on creatinine and eGFR explains what those numbers mean and why muscle mass distorts them.

What happens at the appointment, and what is checked first?

The injection goes under the skin of the upper arm, thigh or abdomen and takes moments. There is no infusion time and no need to stay upright afterwards. Most women arrange it alongside a blood test for calcium and kidney function.

Before starting, three things matter:

• Low blood calcium must be corrected first. Denosumab can lower it further, and the risk is higher with impaired kidney function or low vitamin D. Our page on calcium and vitamin D covers what adequate means.
• Planned invasive dental work is better completed beforehand. Osteonecrosis of the jaw is rare but is associated with extractions and implants during antiresorptive treatment.
• Pregnancy. It is not used in women who may become pregnant.

What rare effects should you be able to name?

Osteonecrosis of the jaw and atypical femoral fracture are both rare and both associated with the antiresorptive class rather than this drug uniquely. Naming them is useful because the early signals are easy to dismiss.

The practical signals are persistent jaw pain or a dental socket that will not heal after work, and new thigh or groin pain that builds over weeks rather than appearing suddenly. Neither is a reason to avoid treatment when fracture risk is high, because the risk being prevented is considerably larger. Both are reasons to report the symptom rather than wait for the next review.

Low blood calcium is the more common problem, and it is why calcium and vitamin D status is checked rather than assumed.

What does good follow-up look like?

• Bone density repeated at an interval your prescriber states rather than left open-ended. See bone density testing for what the scan measures.
• Calcium and kidney function checked around injections.
• The next injection date written down, not left to memory.
• An explicit answer, recorded in your notes, to the question of what happens when treatment ends.
• Weight-bearing and resistance exercise continuing throughout; the drug does not replace it. Our guide to exercise for bone density covers what actually loads bone.

What should you ask before your first injection?

• "How long do you expect me to stay on this, and what is the exit plan?" Ask at the start, not at the end.
• "If I stop, what bridging treatment do you use, and when does it start relative to my last injection?"
• "How much delay is acceptable if a dose slips?"
• "Do I need dental work done before we start?"
• "What are my calcium, vitamin D and kidney numbers now?"

If you are weighing this against other options, our pages on osteoporosis treatment and FRAX fracture risk cover how the decision is usually framed, and menopause and bone loss explains why the years around the final menstrual period matter most.

What does the density gain actually look like over time?

One practical difference from bisphosphonates gets little attention: denosumab keeps building. Bisphosphonate density gains tend to plateau after the first few years, while denosumab produces continued increases across a decade of use. For a woman starting treatment at 60 with a long horizon ahead of her, that matters.

The catch is the same one that runs through this whole page. The longer you have been on it, the more there is to lose if the treatment stops abruptly, and the more carefully the exit needs to be planned. A woman ten years into denosumab has more at stake in a missed injection than one who has had two.

What if you have already missed a dose?

Contact your prescriber rather than waiting for the next scheduled appointment. The point of urgency is that the rebound is time-dependent: bone turnover rises over the months after the drug clears, so the window to restart or bridge is measured in weeks rather than being open indefinitely.

Do not assume a missed dose means starting again from scratch, and do not assume it is fine because you feel no different. Bone loss produces no symptoms until something breaks, which is the entire problem with treating osteoporosis as something you can judge by how you feel.

If height loss or new back pain has appeared during a gap, say so explicitly. Vertebral fractures are frequently painless and are found on imaging rather than reported by the person who has them.

How does this fit with everything else that protects bone?

Denosumab slows breakdown. It does not build muscle, improve balance, or stop you falling, and most fractures happen because someone fell. Treating the drug as the whole intervention is a common and expensive mistake.

The parts that do not come in a syringe: adequate protein intake, resistance training that actually loads the skeleton, balance work, a home falls audit, and reviewing any medicine that causes dizziness or sedation. Our guide to exercise for bone density covers what loading means in practice, and calcium-rich foods covers intake without supplements where possible.

Vitamin D deserves a specific mention here because it is not optional with this drug. Low vitamin D raises the risk of hypocalcaemia after an injection, so it is checked and corrected rather than assumed. See vitamin D for women.